Zai Lab (ZLAB) stock is in focus after China’s National Medical Products Administration approved TIVDAK for adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.

The NMPA approval for TIVDAK comes after a mixed stretch for Zai Lab, with the stock showing a 1-day share price return of 3.87% and a 7-day share price return of 7.58%, yet a 1-year total shareholder return that declined 56.36%. This suggests recent momentum contrasts with a weaker long term track record.

If treatments like TIVDAK have you thinking about where healthcare and AI intersect, it may be worth scanning 41 healthcare AI stocks.

With Zai Lab stock trading at US$17.73 and showing a long term decline in shareholder returns despite analyst targets sitting higher, the question is simple: is the risk already reflected in the price, or is the market already assuming future growth?

Most Popular Narrative: 47.5% Undervalued

Compared with Zai Lab stock at $17.73, the most followed narrative points to a fair value of $33.78. This frames a wide gap investors will want to understand.

Multiple high-potential product launches and label expansions over the next 12-18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.

Want to see what is sitting behind that valuation gap? The most followed narrative leans on brisk revenue expansion, improving margins, and a richer earnings multiple that many investors might not be factoring in yet.

Result: Fair Value of $33.78 (UNDERVALUED)

However, investors in Zai Lab still need to weigh the company’s heavy reliance on in-licensed drugs and the intensifying competition in China, which could pressure margins and future revenue potential.

Another View On Zai Lab Stock

The narrative and analyst targets suggest Zai Lab stock looks 47.5% undervalued on earnings style assumptions, but the picture changes when looking at sales. Zai Lab trades on a P/S of 4.4x versus a fair ratio of 2.9x and a US Biotechs industry average of 10.3x, which points to less obvious upside and some valuation risk if the market moves closer to that fair ratio over time.

For a closer look at how this sales based view compares with peers and the fair ratio the market could drift toward, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern around Zai Lab leaves you undecided, consider acting while sentiment is shifting and carefully weigh both sides using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Zai Lab?

If Zai Lab has your attention, consider broadening your watchlist with a few focused stock ideas that could help sharpen your next move.

• Explore potential opportunities in smaller companies by reviewing 23 elite penny stocks with strong financials, which highlights businesses that may have stronger financial foundations than many investors expect.
• Search for quality at a sensible price through the 44 high quality undervalued stocks, where solid fundamentals and attractive valuations are presented together.
• Consider ways to manage downside risk by scanning the 68 resilient stocks with low risk scores, which concentrates on resilience when conditions become more challenging.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.